## Akshay Sharma

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8751383/publications.pdf

Version: 2024-02-01

516710 254184 2,285 77 16 43 citations g-index h-index papers 86 86 86 3180 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>KMT2A</i> -rearranged AML. Blood Advances, 2022, 6, 828-847.	<b>5.</b> 2	5
2	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Advances, 2022, 6, 339-357.	5.2	35
3	Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.	1.2	13
4	Male-Specific Late Effects in Adult Hematopoietic Cell Transplantation Recipients: A Systematic Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of and Marrow Transplantation. Transplantation and Cellular Therapy, 2022, 28,	1.2	5
5	335.e1-335.e17.  Number of HLA-Mismatched Eplets Is Not Associated with Major Outcomes in Haploidentical Transplantation with Post-Transplantation Cyclophosphamide: A Center for International Blood and Marrow Transplant Research Study. Transplantation and Cellular Therapy, 2022, 28, 107.e1-107.e8.	1.2	5
6	Development of BRAFV600E-positive acute myeloid leukemia in a patient on long-term dabrafenib for multisystem LCH. Blood Advances, 2022, , .	5.2	5
7	Sub-myeloablative Second Transplantations with Haploidentical Donors and Post-Transplant Cyclophosphamide have limited Anti-Leukemic Effects in Pediatric Patients. Transplantation and Cellular Therapy, 2022, 28, 262.e1-262.e10.	1.2	1
8	Preferential expansion of CD8+ CD19-CART cells postinfusion and the role of disease burden on outcome in pediatric B-ALL. Blood Advances, 2022, 6, 5737-5749.	5.2	20
9	Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Bone Marrow Transplantation. 2022, 57, 1150-1163.	2.4	2
10	Viral infection in hematopoietic stem cell transplantation: an International Society for Cell & Description Gene Therapy Stem Cell Engineering Committee review on the role of cellular therapy in prevention and treatment. Cytotherapy, 2022, 24, 884-891.	0.7	3
11	Late pulmonary complications related to cancer treatment in children. Pediatric Radiology, 2022, 52, 2029-2037.	2.0	1
12	Clinical Characteristics and Outcomes of COVID-19 in Pediatric and Early Adolescent and Young Adult Hematopoietic Stem Cell Transplant Recipients: A Cohort Study. Transplantation and Cellular Therapy, 2022, 28, 696.e1-696.e7.	1.2	7
13	Early pulmonary complications related to cancer treatment in children. Pediatric Radiology, 2022, 52, 2017-2028.	2.0	1
14	Comparison of total body irradiation <i>versus</i> non-total body irradiation containing regimens for de novo acute myeloid leukemia in children. Haematologica, 2021, 106, 1839-1845.	<b>3.</b> 5	13
15	Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States. Cancer, 2021, 127, 609-618.	4.1	12
16	CRISPR-Cas9 Gene Editing for Sickle Cell Disease and $\hat{l}^2$ -Thalassemia. New England Journal of Medicine, 2021, 384, 252-260.	27.0	939
17	Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis. Blood, 2021, 137, 556-568.	1.4	34
18	Systematic reviews in hematopoietic cell transplantation and cellular therapy: considerations and guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research late effects and quality of life working committee. Bone Marrow Transplantation, 2021, 56, 786-797.	2.4	5

#	Article	IF	CITATIONS
19	Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematology, the, 2021, 8, e185-e193.	4.6	271
20	Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. Leukemia, 2021, 35, 2076-2085.	7.2	28
21	Outcomes of pediatric patients who relapse after first HCT for acute leukemia or MDS. Bone Marrow Transplantation, 2021, 56, 1866-1875.	2.4	7
22	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 2108-2117.	2.4	6
23	Genetic therapies for the first molecular disease. Journal of Clinical Investigation, 2021, 131, .	8.2	17
24	Single-nucleotide-level mapping of DNA regulatory elements that control fetal hemoglobin expression. Nature Genetics, 2021, 53, 869-880.	21.4	37
25	Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell disease. Blood Advances, 2021, 5, 2403-2411.	5.2	24
26	Base editing of haematopoietic stem cells rescues sickle cell disease in mice. Nature, 2021, 595, 295-302.	27.8	175
27	Reducedâ€intensity conditioning–based hematopoietic cell transplantation for dyskeratosis congenita: Singleâ€eenter experience and literature review. Pediatric Blood and Cancer, 2021, 68, e29177.	1.5	9
28	A polygenic score for acute vaso-occlusive pain in pediatric sickle cell disease. Blood Advances, 2021, 5, 2839-2851.	5.2	14
29	Hemophagocytic lymphohistiocytosisâ€like toxicity (carHLH) after CD19â€specific CAR Tâ€cell therapy. British Journal of Haematology, 2021, 194, 701-707.	2.5	61
30	Targeting plasma cells with daratumumab aids in the treatment of postâ€transplant autoimmuneâ€like hepatitis. Pediatric Blood and Cancer, 2021, 68, e29290.	1.5	3
31	Clinical experience of coronavirus disease 2019 in hematopoietic cell transplant and chimeric antigen receptor T-cell recipients. Current Opinion in Hematology, 2021, Publish Ahead of Print, 394-400.	2.5	4
32	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. Bone Marrow Transplantation, 2021, 56, 3068-3077.	2.4	13
33	Outcomes of pediatric patients with therapy-related myeloid neoplasms. Bone Marrow Transplantation, 2021, 56, 2997-3007.	2.4	4
34	Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2020, 26, 553-561.	2.0	13
35	Improved survival rate in T-cell depleted haploidentical hematopoietic cell transplantation over the last 15 years at a single institution. Bone Marrow Transplantation, 2020, 55, 929-938.	2.4	31
36	Germline Gene Editing for Sickle Cell Disease. American Journal of Bioethics, 2020, 20, 46-49.	0.9	3

3

#	Article	IF	Citations
37	Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor. Haematologica, 2020, 105, e497.	3.5	29
38	Second Allogeneic Hematopoietic Cell Transplant Is a Successful Salvage Modality for Pediatric Patients Who Relapse after First Transplant. Biology of Blood and Marrow Transplantation, 2020, 26, S85-S86.	2.0	0
39	Haploidentical CD45RA-Negative Donor Lymphocyte Infusions Are Feasible, Safe and Associated with Clinical Benefit. Biology of Blood and Marrow Transplantation, 2020, 26, S268.	2.0	3
40	Bringing Known Drugs to Pediatric Research: Safety, Efficacy, and the Ambiguous Minor Increase in Minimal Risk. American Journal of Bioethics, 2020, 20, 106-108.	0.9	4
41	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2020, 26, 1459-1468.	2.0	35
42	Allogeneic Hematopoietic Cell Transplantation Is Critical to Maintain Remissions after CD19-CAR T-Cell Therapy for Pediatric ALL: A Single Center Experience. Blood, 2020, 136, 39-40.	1.4	3
43	Adenosine Base Editing of $\hat{I}^3$ -Globin Promoters Induces Fetal Hemoglobin and Inhibit Erythroid Sickling. Blood, 2020, 136, 21-22.	1.4	8
44	Mitigating Challenges in Dual-Role Consent: Honoring Patient Preferences to Discuss Research Participation With Someone They Know. American Journal of Bioethics, 2019, 19, 30-32.	0.9	5
45	Reduced Intensity Vs Myeloablative Conditioning Regimen for Pediatric Therapy-Related Myelodysplastic Syndrome/Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2019, 25, S14-S15.	2.0	0
46	Genome editing of HBG1 and HBG2 to induce fetal hemoglobin. Blood Advances, 2019, 3, 3379-3392.	5.2	121
47	ASTCT Notes. Biology of Blood and Marrow Transplantation, 2019, 25, 2303-2304.	2.0	0
48	Should Poor Social Support Be an Exclusion Criterion in Bone Marrow Transplantation?. American Journal of Bioethics, 2019, 19, 39-41.	0.9	8
49	Ethical issues in the care of adolescent and young adult oncology patients. Pediatric Blood and Cancer, 2019, 66, e27608.	1.5	22
50	CRISPR-Cas9 Genome Editing of $\hat{I}^3$ -Globin Promoters in Human Hematopoietic Stem Cells to Induce Erythrocyte Fetal Hemoglobin for Treatment of $\hat{I}^2$ -Hemoglobinopathies. Blood, 2019, 134, 2066-2066.	1.4	1
51	Safe and Efficient Peripheral Blood Stem Cell Collection in Patients with Sickle Cell Disease Using Plerixafor. Blood, 2019, 134, 1964-1964.	1.4	0
52	An Extravagant Gift From a Grateful Patient. Pediatrics, 2018, 141, .	2.1	0
53	Indoles derived from intestinal microbiota act via type I interferon signaling to limit graft-versus-host disease. Blood, 2018, 132, 2506-2519.	1.4	120
54	Haploidentical Donor Transplantation Using a Novel Clofarabine-containing Conditioning Regimen for Very High-risk Hematologic Malignant Neoplasms. Journal of Pediatric Hematology/Oncology, 2018, 40, e479-e485.	0.6	3

#	Article	IF	CITATIONS
55	Precision Medicine for Sickle Cell Disease through Whole Genome Sequencing. Blood, 2018, 132, 3641-3641.	1.4	3
56	Sequential Infusion of $Tcr\hat{l}\pm\hat{l}^2$ - and CD45RA-Depleted Haploidentical Progenitor Cells Is Safe and Allows for Rapid Immune Reconstitution in Pediatric Patients with Recurrent Hematological Malignancies. Blood, 2018, 132, 4574-4574.	1.4	0
57	Allogeneic Hematopoietic Cell Transplantation for Acute Megakaryoblastic Leukemia: A Single Center Experience. Biology of Blood and Marrow Transplantation, 2017, 23, S299-S300.	2.0	O
58	Hypocalcemic Tetany After Transfusion of a Small Amount of Blood Product. Journal of Pediatric Hematology/Oncology, 2017, 39, 629-632.	0.6	1
59	Aeromedical Transport of Critically Ill Infants Less Than 3 Months of Age. Global Pediatric Health, 2017, 4, 2333794X1773974.	0.7	O
60	Case 2: Prolonged Hypoglycemia in an Adolescent without Diabetes. Pediatrics in Review, 2016, 37, 304-306.	0.4	1
61	Hematopoietic stem cell transplantation for people with ß-thalassaemia major. The Cochrane Library, 2016, 11, CD008708.	2.8	11
62	Gene therapy for haemophilia. The Cochrane Library, 2016, 12, CD010822.	2.8	9
63	Splenectomy for people with thalassaemia major or intermedia. The Cochrane Library, 2016, , CD010517.	2.8	8
64	Vasculitis Causing Complete Occlusion of Aorta. Journal of Pediatrics, 2015, 167, 206-206.e2.	1.8	1
65	Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva. Journal of Pediatrics, 2015, 166, 204.	1.8	5
66	Dyskeratosis congenita caused by a novel TERT point mutation in siblings with pancytopenia and exudative retinopathy. Pediatric Blood and Cancer, 2014, 61, 2302-2304.	1.5	17
67	Hematopoietic stem cell transplantation for people with $ ilde{A} ilde{Y}$ -thalassaemia major. , 2014, , CD008708.		4
68	Administration of a Tryptophan Metabolite, Indole-3-Carboxaldehyde, Reduces Graft Versus Host Disease Morbidity and Mortality and Enhances Gastrointestinal Barrier Function in a Murine Model of Allogeneic Bone Marrow Transplantation. Blood, 2014, 124, 2420-2420.	1.4	1
69	Sub acute sclerosing pan encephalitis despite adequate vaccination. Australasian Medical Journal, 2012, 5, 359-361.	0.1	6
70	Hematopoietic stem cell transplantation for people with $ ilde{A}\ddot{ ext{Y}}$ -thalassaemia major. , 2011, , CD008708.		4
71	Bilateral cystic nephroma with pleuropulmonary blastoma. BMJ Case Reports, 2011, 2011, bcr0520114171.	0.5	8
72	Writing for publication – raising standards at the AMJ. Australasian Medical Journal, 2011, 4, 225-228.	0.1	1

#	Article	IF	CITATIONS
73	Mortality and morbidity patterns among HIV patients with prognostic markers in a tertiary care hospital in southern India. Australasian Medical Journal, 2011, 4, 273-276.	0.1	3
74	Cochrane: spreading the message of research to students and juniors. , 2011, , ED000026.		2
75	Migration and Health. Australasian Medical Journal, 2008, , 3-8.	0.1	O
76	Designing a Research Mentorship Program (RMP) to enhance research productivity at Ebne-Sina psychiatric hospital. Australasian Medical Journal, 2008, , 180-182.	0.1	2
77	Evidence- Based Medicine for Medical Students. Australasian Medical Journal, 2008, , 190-193.	0.1	4